SCHEMBL2563570

SCHEMBL2563570

CCOC(=O)C1CCc2c1[nH]c1ccc(Br)cc21

nearest known ligand 0.66

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.66
KMT2A Q03164 3/20 0.66
MEN1 O00255 2/20 0.66
LMNA P02545 2/20 0.66
GAA P10253 2/20 0.65
HTT P42858 1/20 0.65
NPSR1 Q6W5P4 1/20 0.65
KDM4E B2RXH2 3/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
SIRT1 Q96EB6 7/20 0.48
ALDH1A1 P00352 4/20 0.47
RECQL P46063 1/20 0.46
SIRT2 Q8IXJ6 1/20 0.46
HIF1A Q16665 1/20 0.46
TP53 P04637 1/20 0.45
ALOX15 P16050 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
DHODH Q02127 1/20 0.44
USP2 O75604 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4154905 0.93 MAPT (0.77) MAPTKMT2AMEN1LMNAGAA
SCHEMBL2566747 0.83 KMT2A (0.62) MAPTKMT2AMEN1LMNAGAA
SCHEMBL3719083 0.83 MAPT (0.67) MAPTKMT2AMEN1LMNAGAA
SCHEMBL2580201 0.81 MAPT (0.68) MAPTKMT2AMEN1LMNAGAA
SCHEMBL2580202 0.81 MAPT (0.68) MAPTKMT2AMEN1LMNAGAA
SCHEMBL16433469 0.80 SIRT1 (0.60) MAPTKMT2AMEN1LMNAGAA
SCHEMBL16266024 0.80 MAPT (0.77) MAPTKMT2AMEN1LMNAGAA
SCHEMBL4725046 0.80 MEN1 (1.00) MAPTKMT2AMEN1LMNAGAA
SCHEMBL31328292 0.80 MAPT (0.77) MAPTKMT2AMEN1LMNAGAA
SCHEMBL31612407 0.80 MEN1 (1.00) MAPTKMT2AMEN1LMNAGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2222668-B1 TETRAHYDROCYCLOPENTA[B]INDOL-3-YL CARBOXYLIC ACID DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS ARENA PHARM INC (US) 2011-11-02 EP disclosed
US-20100273806-A1 TETRAHYDROCYCLOPENTA[B]INDOL-3-YL CARBOXYLIC ACID DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS ARENA PHARMACEUTICALS, INC. (US) 2010-10-28 US disclosed
EP-2222668-A1 TETRAHYDROCYCLOPENTA[B]INDOL-3-YL CARBOXYLIC ACID DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS Arena Pharmaceuticals, Inc. (US) 2010-09-01 EP disclosed
WO-2009078983-A1 TETRAHYDROCYCLOPENTA[B]INDOL-3-YL CARBOXYLIC ACID DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS ARENA PHARMACEUTICALS, INC. (US) 2009-06-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100273806-A1 TETRAHYDROCYCLOPENTA[B]INDOL-3-YL CARBOXYLIC ACID DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS S1PR1, S1PR3, S1PR2 MAPT 3431/4885KMT2A 3974/4885MEN1 1568/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.